Barclays Raises Stryker (NYSE:SYK) Price Target to $443.00

Stryker (NYSE:SYK) had its price target raised by Barclays from $418.00 to $443.00 in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has an overweight rating on the medical technology company’s stock.

Several other research firms have also weighed in on SYK. JMP Securities reissued a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. UBS Group upped their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, Stifel Nicolaus raised their price target on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $420.68.

Stryker Stock Up 0.2 %

Shares of NYSE SYK opened at $392.15 on Monday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market cap of $149.49 billion, a price-to-earnings ratio of 50.53, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. Stryker has a 12-month low of $314.93 and a 12-month high of $406.19. The firm’s 50-day simple moving average is $377.23 and its 200 day simple moving average is $365.14.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business earned $3.46 earnings per share. On average, research analysts expect that Stryker will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio is 43.30%.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by corporate insiders.

Institutional Trading of Stryker

Large investors have recently added to or reduced their stakes in the company. Generali Asset Management SPA SGR acquired a new stake in Stryker in the 4th quarter valued at about $3,384,000. Horizon Investments LLC lifted its position in shares of Stryker by 2.4% in the fourth quarter. Horizon Investments LLC now owns 7,752 shares of the medical technology company’s stock valued at $2,791,000 after buying an additional 181 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Stryker by 3.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 96,868 shares of the medical technology company’s stock worth $34,983,000 after acquiring an additional 3,629 shares during the period. PDS Planning Inc increased its holdings in shares of Stryker by 9.8% during the 4th quarter. PDS Planning Inc now owns 1,562 shares of the medical technology company’s stock worth $562,000 after acquiring an additional 140 shares during the last quarter. Finally, RD Lewis Holdings Inc. acquired a new stake in Stryker during the 4th quarter valued at $285,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.